Biomira Inc. President & CEO To Participate In Cancer Immunotherapy Focus Session At Biotechnology Industry Organization (BIO) CEO & Investor Conference
EDMONTON, Feb. 8 /PRNewswire-FirstCall/ - Biomira Inc. today announced that Alex McPherson, MD, Ph.D., President and Chief Executive Officer, is scheduled to participate in a focus session entitled "Cancer Immunotherapies Coming of Age" at the Biotechnology Industry Organization's 8th Annual BIO CEO & Investor Conference at 9:00 a.m. EST on Tuesday, February 14, 2006. The conference is to be held at The Waldorf- Astoria in New York City.
Dr. McPherson will be joined on the panel by John P. Longenecker, PhD, President & CEO, Favrille Inc., Peter Working, PhD, Senior Vice President, Research and Development, Cell Genesys, Inc., Mitchell Gold, MD, President and CEO, Dendreon Corporation, and Hyam Levitsky, MD, Professor of Oncology, Johns Hopkins University School of Medicine. Mark Monane, MD, Managing Director of Equity Research, Biotechnology and Life Sciences, Needham and Company, LLC, will serve as the panel's moderator.
A webcast recording of the focus session can be accessed at http://ceo.bio.org/opencms/ceo/2006/index.jsp. The Web cast recording will be available approximately 12 hours after the presentation and will be archived until March 14, 2006.
About Biomira
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.
Biomira Inc.CONTACT: Biomira Company Contacts: Media Relations: Bill Wickson, Manager,Public Relations, (780) 490-2818; Investor Relations: Jane Tulloch,Director, Investor Relations, (780) 490-2812; U.S. Media Contact: JonathanBirt, Financial Dynamics, (212) 850-5634, jbirt@fd-us.com; U.S. InvestorContact: John Capodanno, Financial Dynamics, (212) 850-5705,jcapodanno@fd-us.com; To request a free copy of this organization's annualreport, please go to http://www.newswire.ca and click on Tools forInvestors.